Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
fluoropyrimidine · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| oxaliplatin | DRUG | - |
| fluoropyrimidine | DRUG | - |
| bevacizumab | DRUG | - |
The following information on clinical trials is provided for information purposes only to allow patients and physicians to have an initial discussion about the trial. This information is not intended to be complete information about the trial, to contain all considerations that may be relevant to po...
Top 20 of 77 competitors
Fluoropyrimidine is an investigational small molecule being studied for the treatment of colorectal cancer. It is currently in Phase 2 clinical development. The drug is being evaluated in patients with colorectal cancer, and it is not yet approved by regulatory authorities.
Fluoropyrimidine is being developed by Sanofi, a biopharmaceutical company listed on the stock exchange under the ticker SNY. Sanofi is conducting clinical trials to evaluate the drug's safety and efficacy in patients with colorectal cancer.
Fluoropyrimidine is currently in Phase 2 clinical development for the treatment of colorectal cancer. It is an investigational drug, meaning it has not yet been approved by regulatory agencies. The drug is being studied in a clinical trial to assess its effects in patients.
Fluoropyrimidine is being studied in a Phase 2 clinical trial with the identifier NCT00399750, titled 'TREE-2: Three Regimens of Eloxatin in Advanced Colorectal Cancer'. This trial has been completed and enrolled 373 participants with colorectal cancer in the United States.
Fluoropyrimidine is a drug being developed by Sanofi, and it is being studied in a clinical trial that includes Eloxatin as part of the treatment regimens. However, the data provided does not indicate that fluoropyrimidine and Eloxatin are the same drug.